Vertex Pharmaceuticals Incorporated (VRTX) Stock Price & Analysis
Vertex Pharmaceuticals Incorporated (VRTX) closed at USD 535.17 on Thursday, October 22, 2026, up 2.03% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 524.52; the Oct 22, 2026 session ranged USD 521.3–537.73 on volume of 1,641,340 shares. Market capitalization is $135.64B, with a 52-week range of USD 403.16–560.25 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:25 UTC.
Also available as compact Markdown for AI agents: nexqual.com/VRTX.md
Key facts (VRTX)
- Last four reported quarters (through Jun 30, 2026): revenue $12.6B, net income $4.41B (35.0% margin), free cash flow $3.80B (SEC filings).
- Valuation: P/E 30.8x (avg 29.5x at the last 2 fiscal year-ends).
- 2 of 80 tracked superinvestors hold VRTX (13F, Q2 2026): 0 new, 0 added, 2 reduced, 0 unchanged.
- Analysts: Buy (mean 2.03 on a 1–5 scale) (32 analysts), mean target USD 571.46 (range 350–667).
- Total return with dividends: 1Y +26.6% vs S&P 500 +14.9%; 5Y +191.6% vs S&P 500 +80.3%.
- Next earnings: 2026-11-02, EPS estimate USD 0.08, revenue estimate $3.43B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (VRTX)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $7.57B | $8.93B | $9.87B | $11.0B | $12.0B | $12.6B |
| Gross profit | $6.67B | $7.85B | $8.61B | $9.49B | $10.3B | — |
| Operating income | $2.78B | $4.31B | $3.83B | -$233M | $4.17B | $4.78B |
| Net income | $2.34B | $3.32B | $3.62B | -$536M | $3.95B | $4.41B |
| EPS (diluted) | $9.01 | $12.82 | $13.89 | -$2.08 | $15.32 | — |
| Free cash flow | $2.41B | $3.93B | $3.34B | -$790M | $3.19B | $3.80B |
| Gross margin | 88.1% | 87.9% | 87.2% | 86.1% | 86.2% | — |
| Operating margin | 36.7% | 48.2% | 38.8% | -2.1% | 34.8% | 38.0% |
| Net margin | 30.9% | 37.2% | 36.7% | -4.9% | 32.9% | 35.0% |
| Revenue growth | +22.1% | +17.9% | +10.5% | +11.7% | +8.9% | — |
| Cash + short-term investments | $7.52B | $10.8B | $11.2B | $6.12B | $6.61B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (VRTX)
P/E 30.8x · P/S 10.8x · P/FCF 35.7x · P/B 6.7x · FCF yield 2.80% · Earnings yield 3.25% · Buyback yield (TTM) 1.48%
P/E at fiscal year-ends: Dec 2025 29.6x, Dec 2023 29.3x.
Superinvestors (SEC 13F-HR, Q2 2026) (VRTX)
2 of 80 tracked investors hold VRTX. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Tweedy Browne | 1.51% | $19.9M | Reduced -0.7% | |
| Torray Funds | 1.02% | $7.6M | Reduced -1.1% |
Analysts (VRTX)
Consensus Buy (mean 2.03 on a 1–5 scale), 32 analysts; mean target USD 571.46 (low 350, high 667).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-08 | RBC Capital | Target raised | Outperform | $570 → $576 |
| 2026-09-28 | UBS | Target raised | Buy | $585 → $615 |
| 2026-08-05 | Truist Securities | Target raised | Buy | $560 → $565 |
| 2026-08-05 | Barclays | Target raised | Overweight | $615 → $617 |
| 2026-08-04 | TD Cowen | Target raised | Buy | $525 → $550 |
| 2026-08-04 | Cantor Fitzgerald | Target raised | Overweight | $590 → $595 |
| 2026-08-04 | Canaccord Genuity | Target raised | Hold | $436 → $442 |
| 2026-07-13 | UBS | Target raised | Buy | $545 → $585 |
| 2026-07-13 | Truist Securities | Target raised | Buy | $542 → $560 |
| 2026-07-07 | RBC Capital | Target raised | Outperform | $543 → $570 |
| 2026-07-07 | Baird | Target raised | Underperform | $330 → $350 |
Total return (dividends reinvested) (VRTX)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +26.6% | +191.6% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +26.7% | +23.8% |
| Volatility (annualized) | 28.8% | 28.6% |
| Max drawdown | -15.2% (Mar 2026→Apr 2026) | -29.1% (Nov 2024→Aug 2025) |
VRTX analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.08 | $4.91 | -98.4% | $3.43B | 15 |
| Next quarter (ends Dec 2026) | $4.62 | $5.01 | -7.6% | $3.53B | 14 |
| Current fiscal year (ends Dec 2026) | $17.88 | $19.04 | -6.1% | $13.28B | 17 |
| Next fiscal year (ends Dec 2027) | $20.42 | $21.50 | -5.0% | $14.57B | 17 |
Key Statistics (as of October 23, 2026 at 09:25 UTC)
| Price | USD 535.17 |
|---|---|
| Change | ▲ 2.03% (up) |
| Previous Close | USD 524.52 |
| Open | USD 525.62 |
| Day Range | USD 521.3 – 537.73 |
| 52-Week Range | USD 403.16 – 560.25 |
| Volume | 1,641,340 shares |
| Market Cap | $135.64B |
| Exchange | NMS |
Technical Analysis (VRTX)
Nexqual's technical model rates VRTX "BUY" based on 4 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 09:25 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 58.68 (neutral) |
| vs SMA50 | Above (USD 522.56) |
| MACD | -0.15 (negative) |
Analyst Ratings (VRTX)
Wall Street analysts rate VRTX "Buy" based on 32 analysts, with a mean price target of USD 571.46 (range USD 350–667), per Nexqual as of October 23, 2026 at 09:25 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 32 |
| Mean Target | USD 571.46 |
| High Target | USD 667 |
| Low Target | USD 350 |
| Buy / Hold / Sell | 26 / 5 / 1 |
Earnings (VRTX)
| Next Earnings Date | 2026-11-02 |
|---|---|
| EPS Estimate | USD 0.08 |
| Revenue Estimate | $3.43B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 4.73 vs est 4.75 ▼ miss |
| 2026-03-31 | USD 4.47 vs est 4.31 ▲ beat |
| 2025-12-31 | USD 5.03 vs est 5.15 ▼ miss |
| 2025-09-30 | USD 4.8 vs est 4.58 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:25 UTC.
Financials & Fundamentals (VRTX)
| Total Revenue | $12.59B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +12.50% |
| Gross Margin | +54.96% |
| Operating Margin | +38.05% |
| Profit Margin | +35.00% |
| ROE | +23.54% |
| Debt / Equity | 0.1 |
| Current Ratio | 3.19 |
| Total Cash | $7.85B |
| Total Debt | $1.98B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $3.80B (30.2% of revenue) |
Source: Nexqual, October 23, 2026 at 09:25 UTC.
Financial Health Score (VRTX)
Nexqual rates Vertex Pharmaceuticals Incorporated's overall financial health "Strong" across five dimensions, as of October 23, 2026 at 09:25 UTC.
| Growth | Solid — Revenue +9% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 55%, operating 38% (last 12 months) |
| Balance Sheet | Strong — $7.85B cash vs $1.98B debt, net cash position |
| Cash Flow | Strong — FCF $3.80B (last 4 quarters to Jun 2026, SEC), 30% margin |
| Efficiency | Strong — ROE 24%, ROA 11.9% |
Ownership (VRTX)
| Insider Ownership | +0.21% |
|---|---|
| Institutional Ownership | +98.31% |
| Shares Outstanding | 253.46M |
| Float | 252.68M |
| Short % of Float | +2.01% |
Source: Nexqual, October 23, 2026 at 09:25 UTC.
Leadership (VRTX)
Vertex Pharmaceuticals Incorporated is led by Reshma Kewalramani FASN, CEO, President & Director, per Nexqual as of October 23, 2026 at 09:25 UTC.
| CEO, President & Director | Reshma Kewalramani FASN |
|---|---|
| Executive Chairman | Jeffrey Marc Leiden |
| Executive VP, COO & CFO | Charles F. Wagner |
| Executive VP & Chief Product Affairs Officer | Ourania Tatsis |
| Executive VP & Chief Scientific Officer | Mark Bunnage D.Phil |
Major Backers & Investors (VRTX)
Notable institutional backers of Vertex Pharmaceuticals Incorporated include Capital Group, Growth Fund of America, Invesco, according to Nexqual as of October 23, 2026 at 09:25 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Capital Group | 17.97% |
| Growth Fund of America | 5.09% |
| Invesco | 3.17% |
| JPMorgan | 2.57% |
| AMERICAN BALANCED FUND | 2.14% |
| Amcap Fund | 1.87% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.5% |
| Vanguard Group | 8.45% |
| State Street | 4.68% |
| Geode Capital | 2.37% |
Source: Nexqual, October 23, 2026 at 09:25 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| REGN | Regeneron Pharmaceuticals, Inc. | USD 819.09 | ▲ 1.67% |
| MRNA | Moderna, Inc. | USD 202.63 | ▼ 17.57% |
| ARGX | argenx SE | USD 875.76 | ▼ 1.61% |
| ONC | BeOne Medicines Ltd. | USD 382.27 | ▼ 1.08% |
| RVMD | Revolution Medicines, Inc. | USD 187.69 | ▼ 3.39% |
| RPRX | Royalty Pharma plc | USD 63.75 | ▲ 2.57% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:25 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt